In This Article:
-
556 Warrants Z were exercised resulting in the issuance of 695 new ordinary shares
-
Outstanding 2,810,092 Warrants Z remain exercisable until June 20, 2025, with potential to raise up to an additional €702,523
BERLIN, March 28, 2025--(BUSINESS WIRE)--Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides results of the fifth exercise of Warrants Z and an update on the outstanding number of ordinary shares and Warrants Z as of the settlement date taking place today. The exercise of 556 Warrants Z has resulted in the issuance of 695 new shares for gross proceeds of €139.
In the fifth Warrant Z exercise period, from February 24, 2025, to March 21, 2025, holders were entitled for every 4 Warrants Z held to subscribe for 5 new shares at €0.20 per share. Following this exercise, 2,810,092 outstanding Warrants Z remain with the potential to raise an additional €702,523 if exercised in full before the end of the final exercise period on June 20, 2025.
The following numbers of TME Pharma securities are thus issued and outstanding:
-
ALTME ordinary shares (ISIN: NL0015000YE1): 94,186,546
-
Warrants Z (ISIN: NL0015001SR3): 2,810,092
The sixth and final Warrant Z exercise period will run from May 26, 2025, to June 20, 2025, with settlement on June 27, 2025. Warrants Z that have not been exercised by the end of the last exercise period will become null and void (see "Warrant Terms and Conditions" on the TME Rights Issue page for more details).
Additional Information
The characteristics, terms and conditions and dilution resulting from the transaction are summarized in the press releases published on November 24, 2023, November 28, 2023, and February 23, 2024, and in the dedicated Rights Issue page on the TME Pharma website.
Dilution
The table below summarizes the dilution from the new ordinary shares issued today, and the maximum additional dilutive potential for an investor who did NOT participate in the transaction should all potential Warrants Z be exercised. Shareholders who participated fully in the transaction will not be diluted by this transaction.
| Description | Shares to be issued | Total shares outstanding | Dilution (cumulative) | Shareholder starting with 1% on March 27, 2025, would then hold |
| Outstanding shares on March 27, 2025 | - | 94,185,851 | - | 1% |
| Shares Issued on March 28, 2025, from exercise of 556 Warrants Z | 695 | 94,186,546 | 0.00% | 1% |
| Exercise of outstanding Warrants Z (latest on June 20, 2025) | 3,512,615 | 97,699,161 | 3.60% | 0.96% |
About TME Pharma
TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company’s oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA Phase 1/2 clinical trial, TME Pharma is studying its lead drug candidate NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer) in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses, and improved survival. US FDA has approved the design of a randomized Phase 2 trial in glioblastoma and TME Pharma was awarded fast track designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. TME Pharma has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in the United States. The company’s second clinical-stage drug candidate, NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), showing potential to address fibrosis and inflammation is evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect. Further information can be found at: www.tmepharma.com.